<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825394</url>
  </required_header>
  <id_info>
    <org_study_id>270/2015BO1</org_study_id>
    <nct_id>NCT02825394</nct_id>
  </id_info>
  <brief_title>Specific PoC Testing of Coagulation in Patients Treated With DOAC 1</brief_title>
  <acronym>SPOCT-DOAC 1</acronym>
  <official_title>Specific Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Part 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators study aims to test the correlation between the Cascade Abrazo point-of-care
      testing (POCT) device (Helena Laboratories, USA) and plasma levels of apixaban, dabigatran,
      edoxaban and rivaroxaban, and to determine the diagnostic accuracy of POCT to rule out or
      detect relevant levels of direct oral anticoagulants (DOAC) in real-life patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of direct oral anticoagulant (DOAC) plasma concentration with Cascade Abrazo point-of-care testing (POCT) result</measure>
    <time_frame>24 hours</time_frame>
    <description>DOAC concentrations determined by ultra-performance liquid chromatography-tandem mass spectrometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy (sensitivity and specificity) of the Cascade Abrazo POCT to rule out or detect relevant DOAC plasma levels</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based prothrombin time (PT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based activated thromboplastin time (aPTT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based thrombin time (TT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based diluted thrombin time (dTT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based ecarin clotting time (ECT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of DOAC plasma concentrations with laboratory-based anti-Xa activity assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of edoxaban plasma concentrations with CoaguChek point-of-care prothrombin time (PT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of edoxaban plasma concentrations with Hemochron Signature point-of-care prothrombin time (PT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of edoxaban plasma concentrations with Hemochron Signature point-of-care activated thromboplastin time (aPTT) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of edoxaban plasma concentrations with Hemochron Signature point-of-care activated clotting time plus (ACT+) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of edoxaban plasma concentrations with Hemochron Signature point-of-care activated clotting time low-range (ACT-LR) assay</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Anticoagulation With NOAC</condition>
  <arm_group>
    <arm_group_label>apixaban initiation</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>apixaban on-treatment</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran initiation</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran on-treatment</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban initiation</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rivaroxaban on-treatment</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>edoxaban initiation</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>edoxaban on-treatment</arm_group_label>
    <description>N=20</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anti-Xa activity point-of-care testing (aXa-POCT)</intervention_name>
    <arm_group_label>apixaban initiation</arm_group_label>
    <arm_group_label>apixaban on-treatment</arm_group_label>
    <arm_group_label>rivaroxaban initiation</arm_group_label>
    <arm_group_label>rivaroxaban on-treatment</arm_group_label>
    <arm_group_label>edoxaban initiation</arm_group_label>
    <arm_group_label>edoxaban on-treatment</arm_group_label>
    <other_name>Cascade Abrazo with ENOX and ENOX LR test cards</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ecarin clotting time point-of-care testing (ECT-POCT)</intervention_name>
    <arm_group_label>dabigatran initiation</arm_group_label>
    <arm_group_label>dabigatran on-treatment</arm_group_label>
    <other_name>Cascade Abrazo with DTM test cards</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood samples, citrated blood samples and citrated plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Part A: patients, who are newly started on oral anticoagulation with apixaban, dabigatran,
        edoxaban or rivaroxaban for secondary prevention of thromboembolic events.

        Part B: patients, on-treatment with apixaban, dabigatran, edoxaban or rivaroxaban.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part A only: planned initiation of treatment with apixaban, dabigatran, edoxaban or
             rivaroxaban

          -  Part B only: ongoing treatment with apixaban, dabigatran, edoxaban or rivaroxaban

          -  Age ≥ 18 years

          -  Written informed consent by patient

        Exclusion Criteria:

          -  Part A only: intake of vitamin K antagonists or direct oral anticoagulants (DOAC) ≤ 14
             days prior to study participation

          -  Part B only: intake of vitamin K antagonists or different DOAC ≤ 14 days prior to
             study participation

          -  Intake of unfractionated heparin ≤ 12 hours, low-molecular-weight heparin ≤ 24h,
             heparinoids (e.g. fondaparinux) ≤ 72h, or direct thrombin inhibitors other than
             dabigatran ≤ 72h prior to study participation

          -  Part A only: abnormal routine coagulation test values at baseline (defined by INR &gt;
             1.2, Quick &lt; 70% or aPTT &gt; 40 sec)

          -  History of coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sven Poli, MD MSc</last_name>
    <phone>+497071290</phone>
    <phone_ext>68300</phone_ext>
    <email>sven.poli@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Härtig, MD</last_name>
    <phone>+497071290</phone>
    <phone_ext>80417</phone_ext>
    <email>florian.haertig@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Poli, MD MSc</last_name>
      <phone>+497071290</phone>
      <phone_ext>68300</phone_ext>
      <email>sven.poli@uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Florian Härtig, MD</last_name>
      <phone>+497071290</phone>
      <phone_ext>80417</phone_ext>
      <email>florian.haertig@uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Sven Poli</investigator_full_name>
    <investigator_title>MD MSc</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

